File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Efficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women

TitleEfficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women
Authors
Issue Date2005
PublisherHarvey Whitney Books Company. The Journal's web site is located at http://www.theannals.com
Citation
Annals Of Pharmacotherapy, 2005, v. 39 n. 9, p. 1428-1433 How to Cite?
AbstractBACKGROUND: Osteoporosis has become a major health problem worldwide, and the incidence is rising in Asian countries. The aminobisphosphonates are potent inhibitors of bone resorption and are currently the mainstay of treatment for postmenopausal osteoporosis. Dosing frequency will likely affect tolerability and adherence to treatment. OBJECTIVE: To assess the tolerability and efficacy of a once-weekly aminobisphosphonate preparation in improving bone mineral density (BMD) and bone turnover markers in osteoporotic Asian women. METHODS: Chinese postmenopausal women with osteoporosis were randomized to receive either alendronate 70 mg once weekly plus calcium carbonate 500 mg daily (n = 29) or calcium carbonate 500 mg daily (n = 29) for one year. BMD was measured by dual energy X-ray absorptiometry. Markers of bone formation and bone resorption included plasma total alkaline phosphatase and urine N-telopeptides. RESULTS: Treatment with alendronate 70 mg once weekly for one year resulted in significant BMD improvement of 6.1% at the spine, 5.6% at the femoral neck, and 3.5% at the total hip. There was no significant change in the BMD values in the calcium group (spine 1.4%, femoral neck -0.2%, total hip 0%). The BMD response in the alendronate group was significantly different from that in the calcium group at all time points, and the difference was detectable as early as after 3 months of treatment (ANOVA p < 0.001). The changes remained significant after adjusting for age, age at menarche, and years since menopause (p < 0.001). Similarly, the reductions in bone markers at 12 months were significantly different between the 2 treatment groups (plasma total alkaline phosphatase: alendronate 27.9%, calcium 5.4%; urine N-telopeptide: alendronate 55.6%, calcium 11.2%; both p < 0.001). The alendronate regimen was well tolerated, without significant adverse events. CONCLUSIONS: The results confirmed that once-weekly alendronate was efficacious in increasing BMD and reducing bone turnover and was well tolerated in Asian women.
Persistent Identifierhttp://hdl.handle.net/10722/77352
ISSN
2015 Impact Factor: 2.119
2015 SCImago Journal Rankings: 0.863
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorHo, AYYen_HK
dc.contributor.authorKung, AWCen_HK
dc.date.accessioned2010-09-06T07:30:59Z-
dc.date.available2010-09-06T07:30:59Z-
dc.date.issued2005en_HK
dc.identifier.citationAnnals Of Pharmacotherapy, 2005, v. 39 n. 9, p. 1428-1433en_HK
dc.identifier.issn1060-0280en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77352-
dc.description.abstractBACKGROUND: Osteoporosis has become a major health problem worldwide, and the incidence is rising in Asian countries. The aminobisphosphonates are potent inhibitors of bone resorption and are currently the mainstay of treatment for postmenopausal osteoporosis. Dosing frequency will likely affect tolerability and adherence to treatment. OBJECTIVE: To assess the tolerability and efficacy of a once-weekly aminobisphosphonate preparation in improving bone mineral density (BMD) and bone turnover markers in osteoporotic Asian women. METHODS: Chinese postmenopausal women with osteoporosis were randomized to receive either alendronate 70 mg once weekly plus calcium carbonate 500 mg daily (n = 29) or calcium carbonate 500 mg daily (n = 29) for one year. BMD was measured by dual energy X-ray absorptiometry. Markers of bone formation and bone resorption included plasma total alkaline phosphatase and urine N-telopeptides. RESULTS: Treatment with alendronate 70 mg once weekly for one year resulted in significant BMD improvement of 6.1% at the spine, 5.6% at the femoral neck, and 3.5% at the total hip. There was no significant change in the BMD values in the calcium group (spine 1.4%, femoral neck -0.2%, total hip 0%). The BMD response in the alendronate group was significantly different from that in the calcium group at all time points, and the difference was detectable as early as after 3 months of treatment (ANOVA p < 0.001). The changes remained significant after adjusting for age, age at menarche, and years since menopause (p < 0.001). Similarly, the reductions in bone markers at 12 months were significantly different between the 2 treatment groups (plasma total alkaline phosphatase: alendronate 27.9%, calcium 5.4%; urine N-telopeptide: alendronate 55.6%, calcium 11.2%; both p < 0.001). The alendronate regimen was well tolerated, without significant adverse events. CONCLUSIONS: The results confirmed that once-weekly alendronate was efficacious in increasing BMD and reducing bone turnover and was well tolerated in Asian women.en_HK
dc.languageengen_HK
dc.publisherHarvey Whitney Books Company. The Journal's web site is located at http://www.theannals.comen_HK
dc.relation.ispartofAnnals of Pharmacotherapyen_HK
dc.subject.meshAgeden_HK
dc.subject.meshAlendronate - administration & dosage - adverse effects - therapeutic useen_HK
dc.subject.meshAlkaline Phosphataseen_HK
dc.subject.meshAsian Continental Ancestry Groupen_HK
dc.subject.meshBone Densityen_HK
dc.subject.meshCollagen - urineen_HK
dc.subject.meshCollagen Type Ien_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHong Kongen_HK
dc.subject.meshHumansen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshOsteoporosis, Postmenopausal - prevention & controlen_HK
dc.subject.meshPeptides - urineen_HK
dc.subject.meshProspective Studiesen_HK
dc.titleEfficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic womenen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1060-0280&volume=39&spage=1428&epage=33&date=2006&atitle=Efficacy+and+tolerability+of+alendronate+once+weekly+in+Asian+postmenopausal+osteoporotic+womenen_HK
dc.identifier.emailKung, AWC:awckung@hku.hken_HK
dc.identifier.authorityKung, AWC=rp00368en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1345/aph.1E580en_HK
dc.identifier.pmid16076919-
dc.identifier.scopuseid_2-s2.0-23944461031en_HK
dc.identifier.hkuros118433en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-23944461031&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume39en_HK
dc.identifier.issue9en_HK
dc.identifier.spage1428en_HK
dc.identifier.epage1433en_HK
dc.identifier.isiWOS:000231177100005-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridHo, AYY=7402675209en_HK
dc.identifier.scopusauthoridKung, AWC=7102322339en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats